全文获取类型
收费全文 | 53860篇 |
免费 | 5579篇 |
国内免费 | 4153篇 |
专业分类
耳鼻咽喉 | 451篇 |
儿科学 | 616篇 |
妇产科学 | 685篇 |
基础医学 | 6224篇 |
口腔科学 | 1195篇 |
临床医学 | 7214篇 |
内科学 | 7776篇 |
皮肤病学 | 567篇 |
神经病学 | 2667篇 |
特种医学 | 2072篇 |
外国民族医学 | 21篇 |
外科学 | 5288篇 |
综合类 | 9642篇 |
现状与发展 | 21篇 |
一般理论 | 7篇 |
预防医学 | 3935篇 |
眼科学 | 1410篇 |
药学 | 5633篇 |
59篇 | |
中国医学 | 3633篇 |
肿瘤学 | 4476篇 |
出版年
2024年 | 224篇 |
2023年 | 914篇 |
2022年 | 2420篇 |
2021年 | 3027篇 |
2020年 | 2325篇 |
2019年 | 1848篇 |
2018年 | 1960篇 |
2017年 | 1861篇 |
2016年 | 1664篇 |
2015年 | 2480篇 |
2014年 | 3121篇 |
2013年 | 2727篇 |
2012年 | 3988篇 |
2011年 | 4291篇 |
2010年 | 2725篇 |
2009年 | 2248篇 |
2008年 | 2703篇 |
2007年 | 2733篇 |
2006年 | 2595篇 |
2005年 | 2328篇 |
2004年 | 1872篇 |
2003年 | 1992篇 |
2002年 | 1745篇 |
2001年 | 1482篇 |
2000年 | 1292篇 |
1999年 | 1349篇 |
1998年 | 904篇 |
1997年 | 825篇 |
1996年 | 645篇 |
1995年 | 591篇 |
1994年 | 515篇 |
1993年 | 262篇 |
1992年 | 350篇 |
1991年 | 292篇 |
1990年 | 273篇 |
1989年 | 222篇 |
1988年 | 212篇 |
1987年 | 178篇 |
1986年 | 149篇 |
1985年 | 91篇 |
1984年 | 76篇 |
1983年 | 33篇 |
1982年 | 18篇 |
1981年 | 15篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 2篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Gui-Qi Zhu Ke-Qing Shi Sha Huang Gui-Qian Huang Yi-Qian Lin Zhi-Rui Zhou Martin Braddock Yong-Ping Chen Ming-Hua Zheng 《Medicine》2015,94(11)
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment. 相似文献
12.
Xiujuan Tian Zhiying Chen Shaomin Shi Xianwen Wang Wanli Wang Ning Li Jing Wang 《Medicine》2015,94(37)
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), is one of the most leading causes of cancers worldwide. Due to a low 5-year survival rate, highly effective methods for the early detection of OSCC are totally needed. MicroRNAs (miRNAs), as promising biomarkers, can bring insights into tumorigenesis of oral cancers. However, studies on the accuracy of miRNAs detection in OSCC have inconsistent conclusions, leading us to conduct this meta-analysis. The aim of this study was to systematically review the articles investigating the diagnostic value of miRNAs in OSCC.The PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Web of Science were searched (updated to June 11th, 2015) to identify all articles evaluating the diagnostic yield of miRNAs for OSCC. The pooled sensitivity, specificity, and other diagnostic parameters were used to assess the performance of miRNAs assays on OSCC detection. Statistical analysis was conducted by employing the R software.The present meta-analysis comprised 23 studies from 10 articles, including 598 OSCC patients and 320 healthy individuals, available for analysis. The summary receiver operator characteristic (SROC) curve was plotted. Meanwhile, the pooled diagnostic parameters and the area under curve (AUC) were calculated based on all included studies. The pooled diagnostic parameters calculated from all 23 studies were as follows: pooled sensitivity of 0.759 (95% CI: 0.701–0.809), pooled specificity of 0.773 (95% CI: 0.713–0.823) and AUC of 0.832, which indicates a relatively high diagnostic accuracy of miRNAs in differentiating OSCC patients from healthy controls. Meanwhile, In addition, subgroup analyses were conducted to access the heterogeneity between studies, which is based on specimen (serum/plasma/blood/saliva/ tissue) and ethnicity (Asian/Caucasian).In summary, our meta-analysis suggests that miRNAs might be used in noninvasive screening tests for OSCC, which needs further large-scale studies to be validated. 相似文献
13.
目的探讨早期使用十全大补汤联合肠内营养乳剂(TP)治疗胃癌术后(气血两虚证)发生喂养不耐受(FI)的影响因素及对营养指标、中医证候积分的影响。方法回顾性分析术后早期行十全大补汤联合TP治疗的80例胃癌术后(气血两虚)患者的病历资料,根据是否出现FI分为耐受组(34例)和不耐受组(46例)。FI的相关影响因素进行单因素及多因素分析,并观察FI对患者营养指标、中医证候积分的影响。结果单因素分析显示,患者术后第1天下床活动时间、开始肠内营养(EN)的时间、使用营养泵、早期灌肠与FI的发生密切相关(P <0. 05);多因素Logistic回归分析显示,患者第1天下床活动时间≥2 h[OR=0. 022,P=0. 001,95%CI(0. 002,0. 223)]、使用营养泵[OR=0. 021,P=0. 000,95%CI(0. 003,0. 162)]是FI发生的独立危险因素;术后10 d,耐受组患者白蛋白(ALB)、血红蛋白(Hb)升高水平优于不耐受组(P <0. 05),中医证候积分显著低于不耐受组(P <0. 05)。结论胃癌术后(气血两虚证)患者早期给予十全大补汤联合TP治疗开始后,患者第1天下床活动时间不短于2 h、使用营养泵能有效减少FI的发生,并改善了患者的营养状态,减轻了中医临床症状。 相似文献
14.
15.
16.
17.
18.
19.
Zhi-Ran Shi Hua Zhang Xian-Yuan Zhang Wen-Bin Wu 《Journal of Asian natural products research》2016,18(5):443-449
Two new bisamides, aglaiamides A (1) and B (2), along with three known ones (3–5), were isolated from the leaves of Aglaia perviridis. Their structures were established on the basis of detailed spectroscopic analyses. 相似文献
20.